All In Biotech

Free tool

FAERS Monitor: Iqirvo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218860 or its brand name (Iqirvo, Elafibranor). Reports on generic versions are filed under their own applications.

Reports

900

Serious

235

26% of reports

Hospitalization

67

Death reported

36

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue100
  • nausea86
  • pruritus83
  • diarrhoea74
  • product dose omission issue72
  • myalgia68
  • constipation65
  • weight increased61
  • arthralgia57
  • headache44
  • off label use44
  • dizziness43
  • muscle spasms42
  • abdominal pain upper38
  • vomiting38

Reports by year received

View as table
YearReports
20211
202476
2025400
2026423

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,259 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myalgiaSignal689.47.4503
constipationSignal657.05.5330
weight increasedSignal616.45.0273
product dose omission issueSignal725.74.6280
muscle spasmsSignal425.34.0145
pruritusSignal835.04.1270
abdominal pain upperSignal384.33.294
arthralgiaSignal573.22.586
fatigueSignal1003.02.5137
diarrhoeaSignal742.72.279
nauseaSignal862.52.182
dizzinessSignal432.01.521
vomiting381.91.415
headache441.61.211
off label use441.20.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.